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Rising cost of healthcare is a concern worldwide. In Kenya, this has seen insurance 
companies report losses despite increase in premiums. In order to control the rising 
costs, insurance companies have introduced co-payments on healthcare services with 
an aim of controlling utilization by limiting visits, costs, drugs and diagnostics. 
However, the effectiveness of co-payments in reducing utilization is still unclear, 
with some studies arguing that it has little or no effect. A retrospective cross-
sectional study was carried out at AAR Healthcare Kisumu Outpatient Centre 
amongst AAR insurance patients seeking healthcare services at the facility. The 
study sought to determine if presence of a co-payment affects utilization and cost of 
various healthcare services. Data of approximately 3238 AAR insurance patient 
visits over a period of 6 months was obtained from the facility CIMS and ERPS 
systems. Descriptive analysis was done presenting counts (percentages), means 
(standard deviations) and medians (interquartile ranges (IQR)). Bivariate analysis 
tests for differences in the demographic and clinic costs among the co-pay groups 
was done using Chi square tests for categorical variables and one-way analysis of 
variance (ANOVA) and median tests for the continuous variables, presenting the p 
values. Utilisation of health services was analyzed in terms of average cost per visit, 
number of laboratory tests done and number of drugs issued to clients with no co-
payments, those paying Ksh. 50, those paying Ksh. 200 and those paying Ksh. 500 as 
co-payment. The study revealed no significant effect of a co-payment on the 
utilisation of healthcare services.  There was no significant difference in the cost of a 
visit based on the co-payments status. The number of medication prescribed did not 
depend on the co-payment status. There was no significant difference in the 
laboratory tests ordered between those who had co-payment and those who did not 
have a co-payment; however there was a significant difference in the utilisation of 
laboratory tests based on the amount of co-payment paid, with the patient visits with 
a co-payment of Ksh. 50 having significantly less laboratory tests done. The results 
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CHAPTER ONE: INTRODUCTION 
1.1 Background 
Rising healthcare cost is a growing concern world-wide. In order to curtail the rising 
costs, healthcare insurance companies and other third party payers have introduced 
co-payments and other forms of cost sharing (Chernew, Gibson, & Fendrick, 2010). 
Co-payments serve to achieve two aims in a healthcare setting; that is, raising 
revenue in order to subsidize third party payers in cases where their contributions are 
not adequate to cover total health care expenses (Drummond & Towse, 2012) and to 
reduce moral hazard hence making patients consumption of health services rational 
(Gemmill, Thomson, & Mossialos, 2008) 
Use of user charges including co-payments is an on-going debate amongst health 
economics. Arguments in economics that favour user charges are based on the 
concept of allocative efficiency. Resources are perceived to be efficiently allocated 
when people are willing to pay for a commodity at a price that reflects the marginal 
cost of producing the commodity (Reinhardt, 1992). This ensures that only those 
who are willing to pay for a particular commodity should have access to it. In 
addition, it is efficient to provide a harmful or ineffective commodity to those willing 
to pay for it while provision of an effective and beneficial commodity to those unable 
to pay for it is considered inefficient. User charges aid in correcting this by 
reinstating price, therefore availing healthcare to only those who are able and willing 
to pay. Regardless of the health consequences of introduction of user charges, from 
an economic perspective, the subsequent reduction in health use contributes to 
allocative efficiency (Gemmill et al., 2008). 
Various studies have sought to understand the effect of user charges, co-payments 
included, on the utilisation of healthcare services by patients. Utilisation may relate 
to total cost of services received, number of visits, number of drugs issued and 
number of services received. These studies carried out in the United States came up 
with varied conclusions. A study carried out in the department of veteran affairs 
illustrated that an increase in co-payments resulted in a reduction in the number of 
medication obtained by veterans, especially those on a higher number of medication 
(Stroupe et al., 2007). A study on the Medicaid program found that implementation 
of a co-payment on prescription drugs resulted in an immediate decrease in the 
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utilisation of prescription drugs, with no overall change in the trend of utilisation 
(Hartung et al., 2008).  Another study on Medicaid patients with cancer concluded 
that when faced with even moderate co-payments, the patients changed their health 
seeking behaviour. The co-payments did not also result in an overall decrease in the 
cost of healthcare but resulted in more negative consequences. The patients who had 
co-payment imposed on them ended up having more emergency room visits than 
those without co-pays (Subramanian, 2011).  
Therefore, the impact of co-payments on the utilisation of health services is not 
predictable. The focus on patient use of services may seem misplaced since it is the 
doctors that make the decision to prescribe drugs and offer services and selective 
application may actually increase costs. Third party payers may also be levying co-
payments in order to shift the burden of payments to the patients (Gemmill et al., 
2008). This may happen in resource limited settings, like Kenya, and so brings into 
question the actual effect of user charges on the utilisation of healthcare services. 
The health insurance industry has been growing steadily in Kenya in the recent past. 
This has seen the premiums grow by 30.4% in 2016. Despite this, the sector 
registered a total loss of Ksh. 0.78 billion in 2016 up from Ksh. 0.31 billion in 2015. 
(Association of Kenya Insurers, 2016) This overall loss in the industry may be due to 
moral hazard. In order to correct this, most healthcare insurance companies, have 
introduced co-payments on certain groups of patients. The co-payments are mainly 
fixed and are therefore not dependent on the socio-economic status of the 
individuals. Thus, the payments display a regressive pattern when expressed as a 
percentage of consumption (Chuma & Maina, 2012). This may therefore affect 
utilisation of healthcare services, especially amongst those with low incomes despite 
having an insurance cover. A study done in the general population revealed that most 
Kenyans prefer a healthcare model that does not have any co-payments (Mulupi, 
Kirigia, & Chuma, 2013), and so levying of the same may reduce utilisation. 
However, there is inadequate data on how such fees affect utilisation of health 
services amongst those insured by private insurance companies. This study therefore 




The study was carried out at AAR Healthcare Kisumu Outpatient Centre. This is one 
of the 18 Outpatient Centres run by AAR Healthcare Limited in Kenya. The 
organisation also runs other outpatient centres in Uganda and Tanzania, with an 
inpatient facility in Kampala, Uganda. The facility is a typical private out-patient 
facility that caters mostly for the insured urban population in Kisumu. It is located on 
the first floor of Al Imran Plaza along Oginga Odinga Street in Kisumu. AAR 
Healthcare and AAR Insurance, though initially were run as one organisation when 
AAR was a Health Maintenance Organisation (HMO), have since separated with 
each being run independently hence AAR Insurance allows its patients to visit other 
healthcare facilities. 
The Kisumu Outpatient Centre sees an average of 54 outpatient clients in a day, with 
95% of them being insured patients. Clients insured by AAR Insurance account for 
about 35% of the total clients seen in the outpatient centre. The facility employs 11 
staff permanent and contract basis, namely 2 medical doctors, 2 nursing officers, 1 
laboratory technologist, 2 pharmacy technologists, 1 accountant, 1 receptionist, 1 
marketing executive and 1 office assistant.  The facility has a paediatrician, 
Obstetrician and gynaecologist, physiotherapist, nutritionist and sonographer 
employed on a temporary basis. The facility enlists the services of locum staff in all 
departments on a need basis depending on the workload. Services offered at the 
facility include doctors’ and specialists consultation, pharmacy, laboratory services, 
nutritional counselling, physiotherapy, antenatal and postnatal clinics, vaccinations 
and ultrasound imaging services. 
1.2 Problem Statement 
High cost of healthcare is a concern worldwide. In Kenya, this has seen health 
insurance companies reporting losses despite an increase in the premium 
contributions in the last 5 years. This has led to health insurance companies and other 
third party payers introduce gate keeping measures such as co-payments whose main 
purpose is to control utilisation of health services by patients and reduce moral 
hazard (Chernew et al., 2010; Gemmill et al., 2008). 
In certain settings, co-payments have been shown to reduce utilisation of healthcare 
services in terms of number of visits, cost per visit, laboratory tests ordered and 
drugs issued. However, the effectiveness of co-payments in reducing utilisation of 
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healthcare services and healthcare costs is not certain, with some studies showing an 
increase in both utilisation and costs in certain situations where co-payments have 
been levied (Subramanian, 2011). This may be due to reduced access to essential 
medication, hence more emergency department visits and this in the long run led to 
more adverse effects which increased the overall cost of healthcare in such 
individuals. It may also be due to patients demanding more services or more costly 
interventions due to having made a co-payment (Tamblyn et al., 2001). In addition, 
the co-payment is usually levied on a group of patients without considering their 
ability to pay, thus shifting the burden of payments from the third party payers to the 
patients, which promotes inequity in healthcare. This has led some authors to 
recommend use of co-payments selectively in order not to limit access to essential 
services but still cater for personal preferences of those willing to pay. Therefore the 
study seeks to establish the effect of co-payments on utilisation of healthcare services 
at AAR Kisumu Outpatient Centre amongst patients insured by AAR Insurance. This 
will aid in steering the country towards achievement of Universal Healthcare and 
financial risk protection for vulnerable populations.  
1.3 Study Objectives 
1.3.1 Broad Objective 
To determine the effect of co-payments on utilisation of healthcare services by 
patients seeking care at AAR Healthcare Kisumu Outpatient Centre 
1.3.2 Specific Objectives 
I. To assess the association between co-payments and the average cost of 
healthcare services for AAR Insurance patients seeking healthcare 
services at AAR Healthcare Kisumu Outpatient Centre. 
II. To assess the association between co-payments and the average number 
of drugs issued to AAR Insurance patients seeking healthcare services at 
AAR Healthcare Kisumu Outpatient Centre. 
III. To assess the association between co-payments and the average number 
of laboratory tests ordered for AAR Insurance patients seeking healthcare 




1.4 Research Questions 
I. Does the presence of a co-payment affect the average cost of healthcare 
services for AAR Insurance clients seeking health services at AAR 
Healthcare Kisumu Outpatient Centre? 
II. Does the presence of a co-payment affect the average number of drugs 
issued to AAR Insurance clients seeking health services at AAR 
Healthcare Kisumu Outpatient Centre? 
III. Does the presence of a co-payment affect the average number of 
laboratory tests ordered for AAR Insurance clients seeking health services 
at AAR Healthcare Kisumu Outpatient Centre? 
1.5 Justification of the Study 
There is need to control the rising healthcare costs that have resulted into 
catastrophic expenditures leading to impoverishment in Kenya (Xu, James, Carrin, & 
Muchiri, 2005). The high costs have also resulted in losses for the health insurance 
industry in Kenya in successive years, with only few insurance companies reporting 
profits (Association of Kenya Insurers, 2016), hence bringing into question the long 
term future of the industry, and in extension healthcare financing especially for 
employers and those with private insurance covers. The role of co-payments has 
been questioned, with various authors arguing that it does not serve to curtail 
healthcare costs but merely transfers the burden of healthcare financing to the 
patients (Drummond & Towse, 2012; Gemmill et al., 2008).  
Therefore the study seeks to establish the effect of co-payments in utilisation of 
healthcare services. This will help third party payers and insurance companies to 
come up with a better model of controlling moral hazard and the overall costs of 
healthcare services. This, if properly implemented may lead to an improvement in 
financial performance of the private healthcare insurance sector, and this may lead to 
reduced premiums with will benefit both employers and individuals paying for their 
health insurance. The study will aid healthcare providers like AAR Healthcare to 
develop strategies of sustaining their businesses by retaining various categories of 
patients and encouraging utilisation of services in light of attempts by insurance 
companies to curtail utilisation through levying of co-payments. The study will also 
contribute to the WHO policy on sustainable healthcare financing and universal 
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coverage, and its building block on Financing in its Health Systems Framework. The 
study will also contribute to the Sustainable Development Goals (SDGs) number 1, 3 
and 10 that address poverty, good health and well being, and inequalities 
respectively. Lastly, the study will also help achieve Kenya’s vision 2030 Social 
























CHAPTER TWO: LITERATURE REVIEW 
2.1 Overview of Co-payments 
Co-payments are one of the gate-keeping measures designed by third party payers in 
a bid to reduce utilisation of healthcare services. When co-payments are absent, 
patients have no financial disincentive to forgo care, and are likely to only utilize 
care that is useful to them. Hence co-payments serve to reduce moral hazard. 
However, very high co-payments undermine the primary reason why individuals 
insure themselves, that is protection from catastrophic expenditure when they fall ill. 
Co-payments also place unnecessary burdens on the lower income groups and sicker 
members of the society (Gruber, 2006) 
Co-payments are usually implemented in a healthcare system in order to reduce 
moral hazard and encourage patients to use healthcare services rationally (Gemmill 
et al., 2008), hence they serve to reduce utilisation of these services. This is 
especially true for out-patient care which is usually more sensitive to co-payments, 
and so it might be more effective in such a setting (Kupor, Liu, Lee, & Yoshikawa, 
1995). When setting co-payments, the payers need to look at the patients’ willingness 
to pay. If the payments are set too low, then the desired effect is highly unlikely to be 
achieved and so co-payments may not result in reduced utilisation (Drummond & 
Towse, 2012). The same author also argues that if set too high, then co-payments 
may price out those who need the services but cannot afford what has been set. 
Co-payments tend to reduce utilisation of healthcare services. This achieves the goal 
of reducing moral hazard and enhancing allocative efficiency (Gemmill et al., 2008). 
This is because patients tend to misuse services when third parties are paying for the 
services. However, in certain cases, co-payments by reducing utilisation tend to pose 
bigger challenges. In services that are a marker of quality, co-payments may in the 
process of reducing utilisation result in long term negative consequences to the 
health of the patients and the healthcare sector at large (Chernew et al., 2010). Co-
payments in the long run may also be in-effective and hinder universal access to 
healthcare as in the case of a mandatory co-payment introduced in Australia (Laba et 
al., 2015). This may be as a result increased financial burden to families and 
individuals due to increase in out of pocket payments.  
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In certain cases, co-payments have been shown not to affect the overall utilisation of 
healthcare services. A study done on the Medicaid Program showed that co-
payments did not have an effect on the overall utilisation of healthcare services 
(Hartung et al., 2008). Co-payments, by virtue of their effect on utilisation of certain 
services resulted in an increase in emergency department visits due to more adverse 
effects due to failure to access essential services (Subramanian, 2011). Therefore, the 
effects of co-payments on utilisation of healthcare services are not obvious.  
2.2 Effect of co-payments on average cost of healthcare 
When levying co-payments in a healthcare system, the goal is usually to discourage 
utilisation of services by exploiting the patients’ unwillingness to pay, hence the 
expected result is usually lower healthcare expenditures (Baum et al., 2016). Various 
studies have shown that this goal is usually achieved both in the short and long run. 
Co-payments usually steer patients into therapies that are more cost effective and 
offer value for money, and therefore resulting in lower costs of healthcare 
(Drummond & Towse, 2012). This leaves other more expensive services for those 
willing to pay. Since medication form a significant portion of healthcare costs, it has 
been shown that when payers put co-payments on medication not preferred by them, 
patients tend to shift to those preferred by the payer, which in most cases tend to be 
cheaper but offer the same therapeutic benefits (Rector, Finch, Danzon, Pauly, & 
Manda, 2003). This might end up reducing the average cost per visit to a physician. 
Other authors have also argued that co-payments  may help control healthcare costs 
by limiting access to new services such as medication that offer very little additional 
advantages to existing therapies (Garattini & van de Vooren, 2013). This in essence 
helps in reducing the cost of healthcare by limiting access to such products and 
services. Therefore in the above cases, co-payments tend to achieve their objectives.  
However, co-payments may not always reduce the cost per visit for patients. This is 
true in cases where patients with chronic conditions require regular follow-ups and 
so levying of co-payments may reduce these visits, and this may result in long 
increase in cost of healthcare in subsequent visits and also result in detrimental 
health effects (Del Mar, 2014). This is because subsequent visits may become more 
expensive since patients may expect that all their conditions will be catered for in 
these visits. A study carried out on Medicaid patients on cancer treatment showed 
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that the overall cost of treatment increased in 6 months in the intervention group 
where co-payments were introduced as opposed to the control group (Subramanian, 
2011). This may indicate that though utilisation of healthcare services reduced due to 
levying of co-payments, the subsequent visits became more expensive, hence co-
payments did not actually result in reduced healthcare costs. In addition, certain 
authors have argued that reduced expenditure on healthcare when co-payments are 
introduced may only be short term, but in the long run may increase the overall costs 
of care, especially if no cheaper substitutes for the for-gone services are available 
(Stroupe et al., 2007). This may be due to adverse health effects which are more 
costly to treat.  
Co-payments if levied selectively on certain components of healthcare may result in 
a reduction in their utilisation, but increase the utilisation of other services.  For 
example, when co-payments were levied on medication, utilisation of other 
healthcare services increased. Therefore the savings made on medication may end up 
being lost in other areas, hence the overall costs ended up increasing instead of 
decreasing (Tamblyn et al., 2001).  
2.3 Effect of co-payments on drug prescriptions 
Cost of pharmaceuticals, to a great extent specialist medication is a major contributor 
to increasing healthcare costs (Schumock et al., 2016). Therefore control of 
utilisation of drugs and pharmaceuticals can reduce overall healthcare costs. Indeed, 
some studies support the view that levying of co-payments will reduce utilisation of 
pharmaceutical services. A study carried out in the Department of Veteran Affairs 
showed a decrease in the number of medications obtained after increasing co-
payments, with a larger impact on those with higher medication use, low cost drugs 
and over the counter medication (Stroupe et al., 2007). Another study on cancer 
patients on the Medicaid Program showed a decrease in the number of days of supply 
of prescription drugs (Subramanian, 2011). These two studies indicate that co-
payments reduce utilisation of pharmaceutical services especially for patients with 
chronic conditions who utilise these services on a consistent basis. Amongst the 
lower income groups, increases in co-payments result in reduced use of healthcare 
services and medication which in the long run may cause adverse effects on their 
health thus leading to increased use of emergency services (Lu, 2003). Therefore co-
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payments levied on drugs, especially the essential medication may in fact increase 
healthcare costs in the long run due to repeat visits. Therefore integrated measures 
should be adopted to reduce healthcare costs in such populations. 
A study done on Medicaid Population showed no increase in utilisation of 
medication for certain chronic conditions in the short run when co-payments were 
introduced, but also showed a significant decrease in the other patient groups 
(Hartung et al., 2008). This shows that use of co-payments may not achieve its 
intended purpose in some classes of patients, depending on their medical conditions. 
This is also corroborated in a study done by Goldman et al which showed that when 
co-payments are introduced for patients which chronic conditions, it might reduce 
the utilisations of drugs not related to the condition but not reduce utilisation of drugs 
related to the chronic condition (Goldman, Joyce, & Zheng, 2007). These studies are 
contradicted by another one that indicates co-payments, especially when tiered may 
lead to shift from non-preferred to preferred brand medications (Rector et al., 2003). 
These are drugs preferred by the payers, thus co-payments achieve their aim.  
Therefore, the role of co-payments in pharmaceuticals is still a debate. In other cases, 
it has been argued that most of the pharmaceutical products issued have no 
therapeutic uses and are therefore a waste of resources. Majority of them are not 
even opened and used by the recipients (Winkelmann, 2004). Therefore co-payments 
are likely to be effective in such a setting. On the other hand, people with life 
threatening conditions are more price inelastic and will tolerate more co-payments in 
order to obtain their medication. Therefore their demand for the services are not 
driven by moral hazard but by more complex decision making that tends to ignore 
the financial implications (Hirsch, Balu, & Schulman, 2014). Therefore in such a 
population, co-payments may result in catastrophic expenditures which may lead to 
impoverishments especially in low income settings. Other studies have also indicate 
that the number of medication given is usually determined by the physician and has 
little relation to patient preference, hence presence of a co-payment may not 
necessarily affect the number of medications issued (Holloway, Gautam, Harpham, 
& Taket, 2002). This is because patients normally rely on the prescriber’s advice. 
Hence more understanding of the effects of co-payment is necessary to fully 
understand its effects on demand on medication across all classes of patients. 
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2.4 Effect of co-payments on utilisation of laboratory services 
Utilisation of laboratory services is one of the major concerns relating to the increase 
in the overall cost of healthcare. This is because there are many unnecessary tests 
that are routinely performed (Vegting et al., 2011)  hence need to control use of 
diagnostic services. In most cases it is the physician that decides the number of 
laboratory tests to be carried out on a patient, but studies have indicated that 
inappropriate and unnecessary laboratory tests may in fact lead to more consultations 
and false positive results which may increase the overall cost of healthcare in the 
long run. This is rampant in cases where physicians carry out defensive medicine for 
fear of litigation (DeKay & Asch, 1998) , and therefore use of co-payments together 
with physician education on costs may help control such unnecessary visits, hence 
reduction in utilisation of healthcare services. A study carried out in a Cyprus 
Emergency Department revealed the contrary that introduction of a co-payment did 
not result in a decrease in the number of laboratory tests ordered, most likely because 
laboratory test ordering is supplier induced, but resulted in an overall reduction in the 
number of visits to the facility (Petrou, 2016). Therefore the use of co-payments to 
reduce laboratory tests ordered must be integrated with other measures including use 
of guidelines.  
In certain cases, presence of a co-payment has shown no significant changes in 
utilisation of laboratory services, like in a study amongst income Adult Medicaid 
Beneficiaries in Oregon. In this case, there was an overall shift in treatment patterns 
which eventually did not result in any cost reductions (Wallace, McConnell, Gallia, 
& Smith, 2008). Therefore use of co-payments alone may not necessarily reduce 
utilisation of laboratory services. In addition, in cases where laboratory tests are 
primarily for preventive purposes or in acute cases of illnesses, introduction of co-
payments did not result in a decrease in the utilisation of these laboratory services. 
However, in cases where the laboratory cases were for chronic conditions, 
introduction of co-payments resulted in a decrease in utilisation of such tests. The 
absence of a reduction in the preventive and acute laboratory tests may have been 
due to the patients’ awareness of the potential benefits of the tests, while the 
reduction in utilisation in the case of chronic conditions may be due to patients 
understanding the chronic nature of their conditions and therefore deferring these 
tests (Reddy, Ross-Degnan, Zaslavsky, Soumerai, & Wharam, 2014). Therefore the 
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effect of co-payments on utilisation of laboratory services is unpredictable, and 
depends on the patients, physician and the condition under management. 
 
2.5 Conceptual Framework 
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Figure 2.1: Conceptual Framework of Effect of Co-Payments on Utilisation of 
Healthcare Services 
 
The conceptual Framework shows the link between access to care in light of a third 
party payer and presence or absence of a co-payment. The framework focuses on 
financial access which is affected by the presence of a co-payment. Therefore, where 
there is a third party payer, the framework looks at how the presence or absence of a 
co-payment will affect the three measures of utilisation, that is, cost of care, number 






















CHAPTER THREE: METHODOLOGY 
3.1 Study Design 
The study was retrospective, cross-sectional in nature. Patient visit data from one 
insurer, that is AAR insurance, was collected from a 6 month period. Quantitative 
data on average cost per visit, number of laboratory test and dugs issued per patient 
was collected from the facility Customer Information Management System (CIMS) 
and Enterprise Resource Management System (ERPS) was collected and analysed 
based on the different categories of patients.  
3.2 Study Population and Sampling 
The study population is patients insured by AAR Insurance seeking services at AAR 
Healthcare Kisumu Out-Patient Centre. These patients were classified into two 
categories, that is those whose insurance premiums are paid by corporates or 
employers and those who pay for their own premiums. The co-payments are levied 
with most of the individual clients having a co-pay of sh. 500. Corporate patients 
have a co-payment of either Sh. 50, 200, or 500 depending on the corporate.  
Data for AAR Insurance patients who received services at AAR Kisumu Out-Patient 
Centre for a period of 6 months, that is, from April 2017 to September 2017 was 
collected. The initial data included 4769 patient visits of which 1531 visits were 
excluded since the patients in this case did not pay a consultation fee, therefore did 
not meet the inclusion criteria of the study. Therefore, the study population totalled 
to 3238 visits from facility Customer Information Management System (CIMS) and 
Enterprise Resource Management System (ERPS). These were collected and 
analysed based on the different categories of patients.  
Only patients insured by AAR insurance were considered for the study. Patients 
insured by other insurance companies or organisations and private patients paying 
cash for services rendered were not considered for the study. Only AAR insurance 
patients who consulted a doctor during the visit were considered. Patients insured by 
AAR insurance who only visited the facility for only laboratory and pharmacy 




3.3 Data Collection 
Quantitative data for a period of 6 months (April 2017 to September 2017) was 
collected from the facility CIMS and ERPS systems. The system is developed by 
Srishti Software Applications Limited. Data on the average cost per visit, number of 
laboratory tests carried out per and number of drugs issued, together will the 
corresponding number of patients based on the 4 patient groups was collected. The 
data was then entered in the spreadsheet (Appendix 2), cleaned and prepared for 
analysis. 
3.4 Data Analysis 
Data was cleaned and analysed. Descriptive analysis was done presenting counts 
(percentages), means (standard deviations) and medians (interquartile ranges (IQR)). 
Bivariate analysis tests for differences in the demographic and clinic costs among the 
co-pay groups was done using Chi square tests for categorical variables and one-way 
analysis of variance (ANOVA) and median tests for the continuous variables, 
presenting the p values. This was done to analyze the data in order to determine 
variations in utilisation of health services in terms of average cost per visit, number 
of laboratory tests done and number of drugs issued to clients with no co-payments, 
those paying Ksh. 50, those paying Ksh. 200 and those paying Ksh. 500 as co-
payment. Statistical significance was at determined at the 5% level of significance. 
STATA software version 15.1 was used for all the descriptive and bivariate analysis. 
The results are presented in pie charts, tables and graphs.  
3.5 Measures of Reliability and Validity 
The data to be used from the study was obtained from the health facility CIMS and 
ERPS system. The system segregated the various groups of clients and so the data 
obtained is reliable. The spreadsheet in which data will be entered was piloted at the 
AAR Eldoret Outpatient Centre to test its effectiveness. Data was then retrieved from 
the system on two different occasions by different people to ensure observer 
reliability and test-retest reliability. Some of the patient visits were sampled and 
confirmed from the system to ensure accuracy.  
External validity was guaranteed by ensuring that all data within the particular 6 
month period was considered. Though purposive sampling was used, the expected 
15 
 
number of 3238 visits and the fact that the patient group is heterogeneous ensured 
external validity. Content validity was guaranteed as the spreadsheet will be 
structured in a way that it captured all the relevant data relating to utilisation of 
healthcare services and the corresponding presence or absence of a co-payment. 
3.6 Ethical Considerations 
Approval to carry out the study was sought from the Senior Management of AAR 
Healthcare Limited (Appendix 1) before accessing the data from CIMS and ERPS 



















CHAPTER FOUR: PRESENTATION OF RESEARCH FINDINGS 
4.1 Descriptive Statistics 
The analysis data collected over a period of 6 months (from 1st April 2017 to 30th 
September 2017 from AAR healthcare Out-patient Centre in Kisumu. The initial data 
included 4769 patient visits of which 1531 visits were excluded since the patients in 
this case did not pay a consultation fee, therefore did not meet the inclusion criteria 
of the study. Therefore, 3238 patient visits were analysed.  Majority of the visits 
were made by males (2153, 66.5%). Patients under the age of 18 years accounted for 
876 (27.05%) of the visits. The mean age of patients was 31.6 years, with a median 
age of 33.5 years (IQR: 15-45). The mean age of adult patients (18 years and above) 
was 40.67 years. Almost all, 3122 (96.4%) were on a corporate cover, with only 116 
(3.6%) being on individual covers. Of all the patient visits, only 275 (8.5%) were on 
co-payment, with the rest having no co-payment. More than half of the patient visits 
with a co-pay (147 out of 275) paid an amount of Ksh. 500. None of the patients on 
an individual cover had a co-payment. Majority of the patients (90.4%) were seen by 
a General Practitioner. The mean of Consultation (Insurance portion) fee was Ksh. 
1243 (SD= 243.58) and mean of Total Consultation fee was Ksh. 1272 (SD= 
221.03). The mean cost of the lab tests done for the patient visits was Ksh. 835 and 
mean cost of medication was Ksh. 2903. The mean cost of each visit was Ksh. 5149 
(SD= 2717.55). Majority of the patients received two, three or four drugs, that is, 
19.1%, 23.9% and 20.3% respectively. With regards to lab tests, more than half of 










Table 4.1: Descriptive Statistics 
Variable Categories 
Mean (SD)/ Count 
(%) Median (IQR) 
Age (Years) 
 
32 (18.31) 33.5(15-45) 
 
<18 Years (876) 7.12 (27.05%) 
 
 
18 Years and Above 
(2362) 40.67 (72.95%) 
 Gender. Female 1085 (33.5%) 
 
 
Male 2153 (66.5%) 
 Payee Type CORPORATE 3122 (96.4%) 
 
 
INDIVIDUAL 116 (3.6%) 
 Co-pay None 2963 (91.5%) 
 
 
Co-pay 275 (8.5%) 
 Visit Type GP Visit 2927 (90.4%) 
 
 
Specialist Visit 311 (9.6%) 
 Visit Fee (Co-Pay) 
(Ksh.) 0 2963 (91.5%) 
 
 
50 24 (0.7%) 
 
 
200 104 (3.2%) 
 
 
500 147 (4.5%) 




1272 (221.03) 1200(1200-1200) 
Cost of Lab Tests 
(Ksh.) 
 
835 (1463.35) 0(0-1400) 






Other services (Ksh.) 
 
139 (578.67) 0(0-0) 



































Figure 4.1: Distribution of the mean total cost of visit 
Figure 4.2: Percentage Distribution of Number of Drugs Issued 
Figure 4.3: Percentage Distribution of Number of Lab Tests Done 
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4.2 Analysis of the Groups based of Co-Pay Status 
The patient groups are analysed based on those visits that had a co-payment and 
those that did not have a co-payment. The analysis then proceeds to analyze the 
individual co-payment groups. Lastly, the patient visits are divided into those seen by 
a General Practitioner and those seen by a Specialist due to the different consultation 
fees paid and the probable difference in utilisation of services. 
4.2.1 Comparison of patient visits with co-pay and those without co-pay 
This analysis relates to all patient visits with a co-payment and those without a co-
payment. Those visits with a co-payment are grouped as one group while those 
without a co-payment are grouped separately. Results in the table below show no 
significant difference in the mean age among the co-pay groups and the no co-pay 
groups (p value=0.152). There were significantly more males among the "No Co-
pay" group, 1997 (67.4%) vs. 156 (56.7%) in "Co-pay" group (chi square p<0.001). 
There was a significant difference in the proportions under a corporate scheme 
among the "No Co-pay" group with a majority 2916 (98.4%) vs. 206 (74.9%) among 
the "Co-pay" group (Chi square p value <0.001).  
There were no significant differences noted in the costs of lab tests, cost of 
medication, and cost of other services. Patient visits in the “No Co-pay” group had 
the lowest mean total cost of visit of Ksh. 5137 as compared to Ksh. 5279 in the 
“Co-pay” group, however without any statistical significance (p value = 0.405). 
There were no significant differences in the number of drugs issued and also number 









Table 4.2:  Comparison of patient visits with co-pay and those without co-pay (Differences reaching statistical significance are 
highlighted in bold) 




 Test Statistic  
    
Mean (SD)/ Count 
(%) Median (IQR) 
Mean (SD)/ Count 
(%) Median (IQR)  
Age 
 
31 (18) 33(15-45) 33 (21) 34(13-48) T-test, P value  = 0.152 
Gender. F 966 (32.6%)  119 (43.3%)  
Chi square, P value 
<0.001  
 
M 1997 (67.4%)  156 (56.7%)  
 
Corp/Ind CORP 2916 (98.4%)  206 (74.9%)  
Chi square, P value 
<0.001  
 
IND 47 (1.6%) 
 
69 (25.1%) 
  Consultation (Insurance 
portion) 1270 (219) 1200(1200-1200) 943 (292) 1000(700-1000) T-test, P value <0.001  
Total Consultation 1270 (219) 1200(1200-1200) 1290 (244) 1200(1200-1200) T-test, P value =0.159 
Cost of Lab Tests 826 (1465) 0(0-1400) 924 (1445) 0(0-1400) T-test, P value = 0.292  
Cost of Medication 2902 (2226.9) 
2582.41(1425.2-
3899.5) 2914 (2336.48) 
2472.04(1225.36-
4211.35) T-test, P value = 0.936  
Other services 138 (576) 0(0-0) 152 (604) 0(0-0) T-test, P value = 0.689  
Mean Total cost of visit 5137 (2725.36) 
4673.7(3205.59-
6252.1) 5279 (2633.23) 
4868.8(3231.36-




























Figure 4.4: Mean Total Cost of Visit Based on Co-Pay Status (No Statistical 
significance seen, p value =0.405) 
Figure 4.5: Percentage Distribution of Number of Drugs Issued Based on Co-pay 
Status (No statistical significance seen, p value =0.531) 
Figure 4.6: Percentage Distribution of Number of Lab Tests Done Bases on Co-
pay status (No statistical significance seen in the distribution, p value =0.137) 
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4.2.2 Analysis of Combined (GP and Specialist) Patient Visits based on Amount 
of Co-Pay 
This analysis looks at the utilisation of healthcare services for all visits based on the 
amount of co-pay the visits had. Results from the combined analysis show that the 
mean age among the co-pay groups was significantly different, those co-paying Ksh. 
50 were much younger than those paying Ksh. 0, Ksh. 200 and Ksh. 500 (p 
value=0.002) as shown in table 4.3. A significant majority were males among those 
co-paying Ksh. 0 and Ksh. 200 in comparison to the other co-pay groups (p 
value<0.001). Results also showed a significant difference in the proportions under a 
corporate scheme among the co-pay categories, with majority (2916, 98.4% and 24, 
100%) paying Ksh. 0 and Ksh. 50 respectively (Chi square p value <0.001).  
No differences in the mean total consultation fee were observed from the results (p 
value =0.225). There were no significant differences noted in the mean costs of lab 
tests and cost of other services. There was no significant difference in the mean cost 
of medication. There was no significant difference in the mean total cost of a visit 
amongst the groups (p value = 0.065). There was no significant difference in the 
number of drugs issued among the co-pay groups. Overall, there was a significant 








Table 4.3: Analysis of Combined (GP and Specialist) Patient visits (Differences reaching statistical level are highlighted in bold) 
    None   Ksh. 50   Ksh. 200   Ksh. 500   Test Statistic  
















(IQR)   
Age 
 
31 (18) 33 (15-45) 21 (14) 26 (9-31) 32 (17) 34 (20-45) 36 (24) 39 (11-54) 
ANOVA, P 
value =  0.002 


































Chi square, P 
value <0.001  
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1200) 1275 (286) 
1150 (1150-
1150) 1065 (212) 
1000 (1000-
1000) 802 (258) 700 (700-700) 
ANOVA, P 






1200) 1325 (286) 
1200 (1200-
1200) 1265 (212) 
1200 (1200-




value = 0.225   
24 
 
Cost of Labs  
 
826 (1465) 0 (0-1400) 792 (1528) 0 (0-1150) 1022 (1383) 0 (0-1600) 876 (1480) 0 (0-1400) 
ANOVA, P 





























138 (576) 0 (0-0) 0 (0) 0 (0-0) 189 (654) 0 (0-0) 151 (614) 0 (0-0) 
ANOVA, P 
value = 0.523 





















































Figure 4.7: Mean Total Cost of Visit Based on Amount of Co-pay (No significant 
difference seen, p value =0.065) 
Figure 4.8: Percentage Distribution of Number of Drugs based on amount of Co-pay 
(No statistical significance seen in the distribution, p value =0.824) 
 
Figure 4.9: Percentage Distribution of Number of Lab Tests done Based on Amount 
of Co-pay (Statistical significance seen in the distribution, p value <0.001) 
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4.2.3 Analysis of Patient visits to a General Practitioner Based on Amount of 
Co-Pay 
The patient visits seen by a GP accounted for 90.4% (2927) of the visits. This group 
was charged a consultation of Ksh. 1200, which is lower than that for specialist 
visits. There was a significant difference in the mean age among the co-pay groups. 
Those co-paying Ksh. 50 were much younger than those paying Ksh. 200 and Ksh. 
500 (p value<0.001), as shown in table 4.4. There was significant majority of 
females among those co-paying Ksh. 500 in comparison to the other co-pay groups 
(p value<0.001). There was a significant difference in the proportions under a 
corporate scheme among the co-pay categories, with majority 2639 (98.3%) and 20 
(100%) paying Ksh. 0 or Ksh. 50 respectively (p value <0.001). No significant 
differences were noted in the mean cost of lab tests and cost of other services (All p 
values >0.05). There were no differences in the mean cost of medication amongst the 
groups (p value =0.107). Those patients with Ksh. 50 co-pay had the lowest mean 
total cost of visit of Ksh. 4001.49, however without any statistical significance (p 
value = 0.091). There was no significant difference in the number of drugs issued 
amongst the co-pay groups. There was a significant difference in the number of lab 
tests among the co-pay groups (Chi square p <0.001). 
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Table 4.4: Analysis of Patient Visits to a General Practitioner (Differences reaching statistical significance are highlighted in bold) 
    None   Ksh. 50   Ksh. 200   Ksh. 500   Test Statistic  
Varia




























(17.81) 34 (18-46) 
22.05 
(14.35) 26 (9.5-31.5) 
34.17 
(15.83) 35 (25-46) 
40.09 
(22.31) 45 (18-55) 







































Chi square, P value 
<0.001  
 








  Consultation 
(Insurance portion) 
(Ksh.) 1200 (0) 
1200 
(1200-
1200) 1150 (0) 
1150 (1150-
1150) 1000 (0) 
1000 
(1000-
1000) 700 (0) 
700 (700-










1200) 1200 (0) 
1200 (1200-
1200) 1200 (0) 
1200 
(1200-
1200) 1200 (0) 
1200 
(1200-
1200) ANOVA, P value N/A  




(1450.84) 0 (0-1400) 
950 
(1633.05) 0 (0-1400) 
1069.47 
(1417.9) 0 (0-1800) 
940.16 
(1565.31) 0 (0-1400) 
































(497.76) 0 (0-0) 0 (0) 0 (0-0) 
207.14 
(681.67) 0 (0-0) 
107.64 
(505.51) 0 (0-0) 
ANOVA, P value = 
0.243 






















































Figure 4.10: Mean Total Cost of a Visit Based on Amount of Co-Pay for GP Visits 
(No significant difference seen, p value = 0.091) 
 
Figure 4.11: Percentage Distribution of Number of Drugs issued based on amount 
of Co-pay for GP Visits (No statistical significance seen in the distribution, p value 
= 0.510) 
 
Figure 4.12: Percentage Distribution of Number of Lab Tests done based on 





4.2.4 Analysis of Patients visits to a Specialist Based on Amount of Co-Pay 
This analysis looks at the utilisation of healthcare services for visits to a specialist. 
This group consisted of 9.6% (311) of the visits. Results of these visits show a 
significant difference in the mean age among the co-pay groups, those co-paying 
Ksh. 500 were much younger than those paying None, Ksh. 50 and Ksh. 200 (p value 
<0.003).  
There was no difference with regards to gender among the co-pay groups (p value 
=0.432). There was a significant difference in the proportions under a corporate 
scheme among the co-pay categories, with majority (277, 99.6% and 4, 100%) 
paying a co-pay of Ksh. 0 or Ksh. 50 respectively (p value <0.001). There was no 
difference in the mean of consultation (insurance portion) and mean of the total 
consultation costs. There were no significant difference noted in the mean costs of 
lab tests and cost of other services (All p values >0.05). There were no significant 
differences in the mean cost of medication amongst the groups (p value =0.480). 
Patient visits with a co-pay of Ksh. 50 co-pay had the lowest mean total cost of visit 
at Ksh. 3802.83 however without any statistical significance (p value = 0.867). There 
was no difference in the number of drugs issued and also number of lab tests among 




Table 4.5: Analysis of Patient visits to a Specialist (Differences reaching statistical significance are highlighted in bold) 
    None   Ksh. 50   Ksh. 200   
Ksh. 
500    Statistic 
Varia




























(16.03) 14 (6-31) 
18.5 
(13.3) 19 (7-30) 
12.44 
(12.98) 7 (4-10) 
7.05 
(8.57) 3.5 (1-8.5) 






































Chi square, P value 
<0.001  
 







  Consultation 
(Insurance portion) 
(Ksh.) 1950 (0) 
1950 
(1950-
1950) 1900 (0) 
1900 
(1900-
1900) 1750 (0) 
1750 (1750-
1750) 1450 (0) 1450 (1450-1450) 











1950) 1950 (0) 
1950 
(1950-
1950) 1950 (0) 
1950 (1950-
1950) 1950 (0) 1950 (1950-1950) 
ANOVA, P value 
N/A  




(1566.95) 0 (0-0) 0 (0) 0 (0-0) 
522.22 
(834.83) 0 (0-900) 
465 
(621.78) 0 (0-1150) 































(1050.37) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 
425 
(1054.75
) 0 (0-0) 
ANOVA, P value = 
0.669  




















































Figure 4.13: Mean Total Cost of a Visit based on Amount of Co-pay for Specialist 
Visits (No significant difference seen, p value =0.867) 
Figure 4.14: Percentage Distribution of Number of Drugs Issued Based on amount 
of Co-pay for Specialist Visits (No statistical significance seen in the distribution, 
p value =0.130) 
 
Figure 4.15: Percentage Distribution of Number of Lab Tests Done based on 
amount of Co-pay for Specialist Visits (No statistical significance seen in the 
distribution, p value =0.141) 
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CHAPTER FIVE: DISCUSSION, CONCLUSION, RECOMMENDATIONS 
AND LIMITATIONS 
5.1 Discussion 
The study sought to determine the effect of co-payments on utilisation of healthcare 
services by patients seeking care at AAR Healthcare Kisumu Outpatient Centre. The 
study indicated that co-payments had no effect on the overall utilisation and cost of 
healthcare services. This agrees with the findings of a study on Medicaid (Hartung et 
al., 2008), which did not show any significant difference in the total cost of a visit 
between those with a co-payment and those without a co-payment. The current study  
differs with results of other studies that indicated that co-payments reduce the overall 
cost of healthcare (Baum et al., 2016; Drummond & Towse, 2012), or increase the 
overall cost of healthcare (Subramanian, 2011). This may be because the current 
study looked at an aggregate cost of visits and did not follow for individual patients. 
The current study did not also consider the probable reduction of visits due to 
introduction of a co-pay since it was beyond the scope of the study. 
Most of the studies have shown that the increase in healthcare costs is mainly in 
patients with chronic conditions who may have higher costs in later visits due to 
missed opportunities for addressing certain healthcare needs, hence more 
complications which become more expensive to treat (Del Mar, 2014). The patient 
composition in this study was heterogeneous, meaning patients with both acute and 
chronic conditions were considered, hence the different results obtained. The median 
age of the patients in this study was 33.5 years, meaning it was a rather young 
population with a lower incidence of chronic medical conditions.  
The amount of co-payment made also had no effect on the overall cost of a visit. 
Those who paid higher co-payments had no significant higher cost of visit that those 
with lower co-payments. Hence increasing the amount of co-payment may not 
necessarily lead to lower costs of visits, but may affect access to healthcare services. 
The patient visits with a co-payment of Ksh. 50 showed a significant lower total cost 
of a visit as compared to other co-payment groups (Table 4.3). This is because the 
above group is made up of AAR Healthcare employees and their families, who in 
addition to a co-payment of Ksh. 50 have 20% of the cost of drugs deducted from 
their salaries, hence were likely to prefer cheaper medication.  
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The cost of drugs accounted for more than 50% of the total cost of a visit, hence a 
greater effect on the overall cost of healthcare. However, the study showed no 
significant difference amongst the different co-pay groups in regards to the cost and 
number of medication issued. This differs from results of other studies that showed a 
decrease in number of drugs issued after a co-payment was introduced (Stroupe et 
al., 2007; Subramanian, 2011). The current study did not look at the effect after the 
introduction of a co-payment but on the overall prescription patterns between those 
visits with a co-payment and those without. The effects of copayments on number 
and cost of medication issued are more pronounced on those patients with chronic 
conditions. However, the current study was carried out on a heterogeneous patient 
population with a mixture of both acute and chronic conditions; hence this might 
have contributed to the lack of difference noted. Other studies have also noted that 
the number of medication issued is dependent on the prescriber (Holloway et al., 
2002), hence this may explain the findings. The current study did not distinguish 
utilisation of healthcare services based on the provider. 
In the utilisation of laboratory services, the study showed no significant difference in 
the number and cost of laboratory tests done between those with co-payments and 
those without co-payments. This is consistent with results from a study done in 
Cyprus that showed that introduction of co-payments did not result in a decrease in 
laboratory tests ordered (Petrou, 2016). This may be because laboratory tests are 
supplier induced and therefore presence of a co-payment is unlikely to reduce their 
utilisation. However, there was a significant difference between the groups with a co-
payment on the utilisation of laboratory services, with those paying Ksh. 50 having 
less laboratory tests done. As explained earlier, this group consists of AAR 
Healthcare staff and their families who in addition to the co-payment of Ksh. 50 have 
a 20% deduction on their pay on the cost of laboratory tests; hence they are likely to 
have a lower utilisation of laboratory services. The co-payment in this study was 
made at the point of registration of the patients, meaning that subsequent services 
provided were unlikely to be affected by its presence or absence; hence the 
healthcare workers had the freedom to request any tests irrespective of the co-
payment status. Other studies have argued that co-payments may increase the 
number of services demanded by the patients due to missed opportunities in 
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previously due to the presence of a co-payment being a deterrent to access to 
services, but this was not noted in the current study. 
5.2 Conclusion 
Co-payments have no effect in the utilisation of healthcare services once the co-
payment is made, but may have an effect on the access to services due to its role in 
reducing unnecessary visits to hospitals, hence reducing moral hazard. The amount 
of co-payment made also has no significant effect on the utilisation and overall cost 
of healthcare services. Co-payments in most cases (the current study included) are 
usually made at the point of registration of a patient. They may therefore reduce 
access to care but may not reduce utilisation of individual healthcare services, since 
their utilisation is now not dependent on the co-payment. Thus, co-payments may be 
used to drive patients to preferred healthcare providers by imposing co-payments on 
visits to those providers considered expensive, thus reducing utilisation of healthcare 
services and overall healthcare costs 
5.3 Recommendations 
In order to fully achieve the intended purpose, co-payments should be made at the 
point of offering a particular healthcare to a patient. This will directly impact 
utilisation of individual healthcare services, hence more effective in controlling 
costs. However, this measure may deny patients’ quality of care since they may not 
be able to access certain services they may need. Co-payments, as applied in this 
study serve more to control access but not the overall cost at the point of utilisation. 
In addition, the amount of co-payment made seems to have no effect on the overall 
cost of individual healthcare services, thus the co-payments should be priced at a 
level that does not hinder access. This can be achieved by pricing the co-payments 
based on the economic status or the average monthly income of an individual. 
5.4 Limitations of the study 
The study was carried out in only one facility and only one insurance company was 
considered. While limited in scale, it is likely that results from a typical facility and a 
well-established insurer in Kenya are generalisable. However, this requires to be 
examined in a larger study. In addition, the utilisation of health services may have 
been influenced by the doctor attending to the patient.  However, it was not possible 
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to look at provider-specific differences in this data set. The patient distribution 
amongst the three classes of patients considered for the study in terms of acute and 
chronic conditions is not certain; hence the study was not able to differentiate 
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